{"analyses":[{"groupDescription":"Best PSA Response Enzalutamide Vs. Bicalutamide.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","statisticalMethod":"Wilcoxon rank sum test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-100.0","upperLimit":"287.7","value":"-92.96"},{"groupId":"OG001","lowerLimit":"-99.8","upperLimit":"25700.0","value":"0.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"168"}],"units":"Participants"}],"description":"The best PSA response was defined as the percentage change from Baseline to the smallest PSA value after Baseline including PSA results from samples taken after the study drug was stopped. For participants with no decrease in PSA post-baseline, the best PSA response was the smallest increase in PSA. For participants with no post-baseline PSA values, the PSA response was set to missing. PSA was analyzed at a central laboratory.","dispersionType":"Full Range","groups":[{"description":"Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.","id":"OG000","title":"Enzalutamide"},{"description":"Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.","id":"OG001","title":"Bicalutamide"}],"paramType":"MEDIAN","populationDescription":"Full analysis set with available PSA data","reportingStatus":"POSTED","timeFrame":"Baseline to the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.","title":"Best PSA Response","type":"SECONDARY","unitOfMeasure":"percent change"}